Under the Skin: What Subcutaneous Isatuximab Means for Myeloma Care

Matthew Lei, PharmD, BCOP, a clinical oncology pharmacist at Massachusetts General Hospital in Boston, joins this episode to unpack the recent FDA approval of subcutaneous isatuximab-irfc (Sarclisa Escena), delivered via the CirCLIQ on-body injector. He walks through what actually changes at the formulation level—a hyaluronidase-free, fixed 1,400 mg/10 mL dose—and why isatuximab’s distinct binding epitope and complement-independent cytotoxicity may offer a mechanistic edge in patients with 1q21 abnormalities, who make up 40–50% of frontline myeloma patients. The conversation grounds this in the phase 3 IRAKLIA trial, which showed near-identical response rates between subcutaneous and IV isatuximab (71.1% vs 70.5%) alongside a dramatic drop in infusion reactions (roughly 1.5% with the on-body injector versus 20% with IV).

From there, Lei gets into what the on-body injector actually changes at the point of care—hands-free, pressure-controlled delivery that adjusts to a patient's subcutaneous tissue, and early patient/provider preference data favoring it over both IV and manual subcutaneous push. He's candid about the operational lift this creates for pharmacy and nursing workflows, from cold-chain storage to nurse training to the reimbursement shift from medical to prescription billing that could strain community oncology practices. The episode closes by weighing isatuximab against subcutaneous daratumumab—not as competing brands but as two distinct tools—and lands on what Lei calls the single biggest win: a formulation that's measurably less painful for patients cycling through induction, consolidation, and maintenance therapy.